Quest Diagnostics Inc vs Standard Lithium Ltd — how do they compare? Quest Diagnostics Inc trades at $231.03 (market cap $25.48B), while Standard Lithium Ltd trades at $1.62 (market cap $398.07M). The key difference: Quest Diagnostics Inc is far larger — about 64× Standard Lithium Ltd's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Standard Lithium Ltd for 23 Days on average.
| DGX | SLI | |
|---|---|---|
Market Cap | $25.48B | $398.07M |
Volume | 941,866 | 1,564,155 |
Sector | Health | Basic Materials |
52-Week High | $247.45 | $5.65 |
52-Week Low | $173.49 | $1.61 |
Typical Hold Time | 56 Days | 23 Days |
Enterprise Value | $31.23B | $260.98M |
Dividend Yield | 1.49% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Standard Lithium (SLI) trades at $1.615, down 2.12% today, with a bearish technical signal despite oversold RSI readings. The company shows negative profitability with ROE at -15.55% and no revenue in 2025, but has achieved key project milestones including customer offtake agreements with LG Energy Solution and Trafigura. Analyst consensus remains strongly bullish with a $3.83 price target, reflecting optimism about the Arkansas lithium project's 2026 final investment decision.
The investment case hinges on successful execution of the South West Arkansas lithium project, which could transform SLI from development to production phase. Key risks include project delays, funding requirements, and lithium price volatility. With 100% analyst buy ratings and institutional backing from BlackRock and Amundi, the stock offers high-risk, high-reward potential for investors betting on North American lithium production growth.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →